Re: an economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
DiSantostefano
Rachel L
RL
Biddle
Andrea K
AK
Lavelle
John P
JP
D000317:Adrenergic alpha-Antagonists / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D017292:Doxazosin / Q000191:economics* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000191:economics* / Q000627:therapeutic use; D018120:Finasteride / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000191:economics; D019057:Quality-Adjusted Life Years
D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D018120:Finasteride; D017292:Doxazosin